We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
CABOMETYX Ipsen Pty Ltd
Product name
CABOMETYX
Sponsor
Accepted date
Nov-2024
Active ingredients
cabozantinib (S)-malate
Proposed indication
CABOMETYX is used to treat adult patients with particular types of advanced or spreading pancreatic or extra-pancreatic neuroendocrine tumours who have already received prior treatment.
Application type
C (new indication)
Publication date
Nov-2024